ECB-ART-50027
Onco Targets Ther
2015 Jan 05;8:2399-406. doi: 10.2147/OTT.S89225.
Show Gene links
Show Anatomy links
The distinctive nature of adenocarcinoma of the lung.
Roviello G
.
???displayArticle.abstract???
In recent years, many personalized treatments have been developed for NSCLC (non-small-cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for patients with EGFR gene mutations, while crizotinib and ceritinib are two new tyrosine kinase inhibitors directed against the echinoderm microtubule-like protein 4-anaplastic lymphoma kinase translocation. The possibility of these new molecules being used to treat patients without adenocarcinoma histology is notably small. For example, EGFR mutations and anaplastic lymphoma kinase fusion gene rearrangement are rare in patients with squamous cell carcinoma (generally <1%). Additionally, the benefit of targeted treatment approaches in patients with small-cell lung cancer histology is limited. All of these findings highlight the distinctive nature of adenocarcinoma of the lung among all lung cancer subtypes. Unfortunately, to date, less than 15% of patients with adenocarcinoma of the lung are ideal candidates for these targeted therapies.
???displayArticle.pubmedLink??? 26366094
???displayArticle.pmcLink??? PMC4562731
???displayArticle.link??? Onco Targets Ther
References [+] :
Annema,
Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer.
2005, Pubmed
Annema, Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer. 2005, Pubmed
Arcaro, Targeted therapies for small cell lung cancer: Where do we stand? 2015, Pubmed
Bergethon, ROS1 rearrangements define a unique molecular class of lung cancers. 2012, Pubmed
Brahmer, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. 2015, Pubmed
Brevet, Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. 2011, Pubmed
Camidge, Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. 2010, Pubmed
Cancer Genome Atlas Research Network, Comprehensive molecular profiling of lung adenocarcinoma. 2014, Pubmed
Cappuzzo, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. 2005, Pubmed
Cappuzzo, MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. 2009, Pubmed
Chen, Inhibitors of the polymerase chain reaction in Papanicolaou stain. Removal with a simple destaining procedure. 1996, Pubmed
Choi, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. 2010, Pubmed , Echinobase
Ciardiello, EGFR antagonists in cancer treatment. 2008, Pubmed
Doebele, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. 2012, Pubmed
Drilon, Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. 2013, Pubmed
Dungo, Afatinib: first global approval. 2013, Pubmed
Engelman, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 2007, Pubmed
Gainor, Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. 2013, Pubmed
Gainor, ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. 2013, Pubmed
Giaccone, EGFR inhibitors: what have we learned from the treatment of lung cancer? 2005, Pubmed
Govindan, Overcoming resistance to targeted therapy for lung cancer. 2015, Pubmed
Gridelli, ALK inhibitors in the treatment of advanced NSCLC. 2014, Pubmed , Echinobase
Gu, Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. 2009, Pubmed
Gupta, The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. 2009, Pubmed
Hammerman, Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. 2011, Pubmed
He, Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. 2009, Pubmed
Hernández, TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. 1999, Pubmed
Hirsch, EGFR testing in lung cancer is ready for prime time. 2009, Pubmed
Hynes, ERBB receptors and cancer: the complexity of targeted inhibitors. 2005, Pubmed
Iragavarapu, Novel ALK inhibitors in clinical use and development. 2015, Pubmed
Jänne, Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. 2011, Pubmed
Jänne, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. 2015, Pubmed
Katayama, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. 2012, Pubmed
Kimura, Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. 2006, Pubmed
Kwak, Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. 2005, Pubmed
Kwak, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010, Pubmed
Langer, Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? 2013, Pubmed
Lindeman, Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013, Pubmed
Lynch, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 2004, Pubmed
Maheswaran, Detection of mutations in EGFR in circulating lung-cancer cells. 2008, Pubmed
Mano, Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. 2008, Pubmed , Echinobase
Miller, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. 2012, Pubmed
Mitsudomi, Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. 2010, Pubmed
Ou, ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. 2012, Pubmed
Oxnard, Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer. 2012, Pubmed
Oxnard, Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. 2011, Pubmed
Paez, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 2004, Pubmed
Palmer, Anaplastic lymphoma kinase: signalling in development and disease. 2009, Pubmed , Echinobase
Pao, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. 2005, Pubmed
Pao, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005, Pubmed
Petrioli, Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study. 2015, Pubmed
Petrioli, Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. 2015, Pubmed
Reck, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. 2009, Pubmed
Riely, Update on epidermal growth factor receptor mutations in non-small cell lung cancer. 2006, Pubmed
Rosell, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. 2012, Pubmed
Rosell, Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. 2011, Pubmed
Rosell, Screening for epidermal growth factor receptor mutations in lung cancer. 2009, Pubmed
Sandler, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. 2006, Pubmed
Sasaki, The biology and treatment of EML4-ALK non-small cell lung cancer. 2010, Pubmed , Echinobase
Sasaki, The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. 2010, Pubmed
Savic, Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. 2008, Pubmed
Scagliotti, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. 2008, Pubmed
Sequist, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 2013, Pubmed
Sequist, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. 2011, Pubmed
Sequist, Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. 2010, Pubmed
Sequist, Rociletinib in EGFR-mutated non-small-cell lung cancer. 2015, Pubmed
Seto, CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. 2013, Pubmed
Seto, Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. 2014, Pubmed
Shaw, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009, Pubmed
Shaw, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. 2013, Pubmed
Shaw, Ceritinib in ALK-rearranged non-small-cell lung cancer. 2014, Pubmed
Shepherd, Erlotinib in previously treated non-small-cell lung cancer. 2005, Pubmed
Smith, Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. 2008, Pubmed
Smouse, EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. 2009, Pubmed
Soda, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007, Pubmed , Echinobase
Solomon, First-line crizotinib versus chemotherapy in ALK-positive lung cancer. 2014, Pubmed
Soria, Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. 2015, Pubmed
Soria, Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. 2015, Pubmed
Suda, Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. 2012, Pubmed
Sørensen, Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. 1988, Pubmed
Takahashi, Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. 2010, Pubmed , Echinobase
Takeuchi, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. 2009, Pubmed
Takeuchi, RET, ROS1 and ALK fusions in lung cancer. 2012, Pubmed
Tournoy, EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. 2009, Pubmed
Ulivi, Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. 2013, Pubmed , Echinobase
Ulivi, Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. 2012, Pubmed
Ulivi, EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients. 2012, Pubmed
Wong, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. 2009, Pubmed , Echinobase
Yasuda, EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. 2012, Pubmed
Zeng, Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. 2015, Pubmed
Zhang, Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. 2010, Pubmed